[144] Twist Bioscience Corporation SEC Filing

Rhea-AI Filing Summary

Twist Bioscience (TWST) insider sale notice: This Form 144 reports a proposed sale of 521 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $13,527.35. The company has 60,360,925 shares outstanding and the sale is planned for 08/21/2025 on NASDAQ.

The shares were acquired on 08/20/2025 by restricted stock vesting as compensation and became payable on the same date. The filer previously sold common shares in six transactions between 05/21/2025 and 08/04/2025, totaling 2,022 shares for gross proceeds of $60,115.91. The filer certifies no undisclosed material adverse information.

Positive

• Compliance with Rule 144 is documented, indicating the sale follows SEC transfer restrictions and disclosure requirements
• Sale size is small (521 shares, ~$13.5k) relative to total outstanding shares, implying minimal market impact
• Shares were acquired via restricted stock vesting, a standard compensation mechanism rather than an unrelated purchase

Negative

• Insider sales continued (2,022 shares sold between 05/21/2025 and 08/04/2025), which could be perceived negatively by some investors as ongoing insider liquidity
• Immediate sale after vesting (acquired 08/20/2025, planned sale 08/21/2025) may raise questions about the insider's intent to hold shares long term

Insights

Securities Analyst

TL;DR Insider plans to sell newly vested shares totaling 521 shares; prior sales show ongoing modest dispositions.

From a trading-impact perspective, the reported sale size (521 shares, ~$13.5k) is immaterial relative to the issuer's outstanding shares (60.36 million), suggesting limited market impact. The shares were acquired via restricted stock vesting and are being sold under Rule 144, which is a routine compliance pathway for insiders to liquidate compensation-related equity. Recent prior sales totaling 2,022 shares over several months indicate an ongoing pattern of modest dispositions rather than a single large exit.

Corporate Governance Expert

TL;DR The filing documents compliant insider disposals of compensation-related stock, with required attestation about undisclosed material information.

Governance-wise the filer affirms no undisclosed material adverse facts and references Rule 10b5-1 plan language in the remarks. The acquisition date (08/20/2025) and immediate planned sale date (08/21/2025) reflect post-vesting liquidity events. The sequence of small sales across multiple dates may warrant investor attention only for signaling, but the absolute sizes are small and consistent with compensation monetization rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	521	13527.35	60360925	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Restricted Stock Vesting	Issuer			521	08/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	05/21/2025	531	15795.87
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	06/06/2025	257	8159.65
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	06/16/2025	94	3146.65
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	06/20/2025	230	8223.58
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	07/02/2025	125	4524.14
Dennis H. Cho 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	785	22265.82

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for TWST report?

The Form 144 reports a proposed sale of 521 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $13,527.35, planned for 08/21/2025 on NASDAQ.

How were the 521 shares acquired by the filer?

The shares were acquired on 08/20/2025 by restricted stock vesting and the payment nature is listed as compensation.

Have there been recent sales by the same filer?

Yes. The filer sold 2,022 shares in six transactions between 05/21/2025 and 08/04/2025, generating total gross proceeds of $60,115.91.

How large is this sale relative to Twist Bioscience's share count?

The 521-share sale represents an immaterial portion of the issuer’s reported 60,360,925 shares outstanding.

Does the filer assert any undisclosed material information?

By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.